This Article Full Text (PDF) All Versions of this Article: 1076029609338710v1 15/4/395    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Viskov, C. Articles by Fareed, J. PubMed PubMed Citation Articles by Viskov, C. Articles by Fareed, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Thinners Hazardous Substances DB METHANOL SODIUM METHOXIDE Social Bookmarking                         What's this?

Isolation and Characterization of Contaminants in Recalled Unfractionated Heparin and Low-Molecular-Weight Heparin

sanofi-aventis, Vitry sur Seine, France, Viskov{at}sanofi-aventis.com

E. Bouley, MS

sanofi-aventis, Vitry sur Seine, France

P. Hubert, MS

sanofi-aventis, Vitry sur Seine, France

Celine Martinez, MS

sanofi-aventis, Vitry sur Seine, France

F. Herman, PhD

sanofi-aventis, Vitry sur Seine, France

Walter Jeske, PhD

Loyola University Medical Center, Maywood, Illinois

Debra Hoppensteadt, PhD

Loyola University Medical Center, Maywood, Illinois

Jeanine M. Walenga, PhD

Loyola University Medical Center, Maywood, Illinois

Jawed Fareed, PhD

Loyola University Medical Center, Maywood, Illinois

Recently, a contaminant was found in some clinically used unfractionated heparin (UFH) preparations. Administration of this UFH was associated with an increased risk of developing a wide range of adverse effects including death. To further investigate the chemical profile of the contaminant, contaminated batches of UFH were treated by exhaustive nitrous acid depolymerization followed by methanol precipitation to remove heparin oligosaccharides. Because contaminated heparins may have been used as starting material in the production of low-molecular-weight heparins (LMWHs), a similar procedure was carried out using an experimental batch of enoxaparin prepared from contaminated heparin. While high-pressure liquid chromatography (HPLC) analysis of contaminated heparin did not distinguish the presence of the contaminant, it could readily be observed as a high-molecular weight shoulder in the elution profile of contaminated enoxaparin. Digesting contaminated heparin with heparinase-I prior to HPLC analysis showed the presence of a nondigestible component (15%-30% of the mixture). This contaminant was also resistant to degradation by chondroitinases A, B, and C. Proton nuclear magnetic resonance (NMR) indicated that the contaminant was oversulfated chondroitin sulfate (OSCS). Size-exclusion chromatography indicated that the mean molecular weight of the OSCS was 16.8 kD, comparable to that of a synthetic porcine cartilage OSCS preparation that was used as a reference material (17.2 kD). While varying degrees of high-molecular weight dermatan sulfate and other minor impurities were detected, OSCS appeared to be the major contaminant in these preparations. The process involved in the production of enoxaparin does not significantly degrade OSCS.

Key Words: heparin • oversulfated chondroitin sulfate • low-molecular-weight heparin

This version was published on August 1, 2009

Clinical and Applied Thrombosis/Hemostasis, Vol. 15, No. 4, 395-401 (2009)
DOI: 10.1177/1076029609338710


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?